John C Morris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9724574/publications.pdf

Version: 2024-02-01

436 papers	105,968 citations	416 132 h-index	213 310 g-index
451 all docs	451 docs citations	451 times ranked	57558 citing authors

#	Article	IF	Citations
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.4	12,681
2	The Clinical Dementia Rating (CDR). Neurology, 1993, 43, 2412.	1.5	7,882
3	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.9	4,117
4	Association of missense and 5â€²-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393, 702-705.	13.7	3,333
5	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	13.9	3,005
6	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
7	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
8	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	1.7	1,839
9	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
10	Decreased Clearance of CNS Î²-Amyloid in Alzheimerâ€™s Disease. Science, 2010, 330, 1774-1774.	6.0	1,704
11	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
12	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
13	Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimerâ€™s Disease. Journal of Neuroscience, 1996, 16, 4491-4500.	1.7	1,570
14	Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's disease. Annals of Neurology, 1999, 45, 358-368.	2.8	1,569
15	Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. Archives of Neurology, 2001, 58, 397-405.	4.9	1,532
16	Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type. International Psychogeriatrics, 1997, 9, 173-176.	0.6	1,190
17	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid AÎ²42in humans. Annals of Neurology, 2006, 59, 512-519.	2.8	1,190
18	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166

#	Article	IF	Citations
19	Alzheimerâ€™s Disease: The Challenge of the Second Century. Science Translational Medicine, 2011, 3, 77sr1.	5.8	1,109
20	A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage, 2004, 23, 724-738.	2.1	1,105
21	Bloodâ€“brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine, 2019, 25, 270-276.	15.2	987
22	Human apoE Isoforms Differentially Regulate Brain Amyloid-Î² Peptide Clearance. Science Translational Medicine, 2011, 3, 89ra57.	5.8	924
23	The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals. Cerebral Cortex, 2009, 19, 497-510.	1.6	861
24	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 2017, 549, 523-527.	13.7	852
25	Cerebrospinal Fluid tau/Î²-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults. Archives of Neurology, 2007, 64, 343.	4.9	841
26	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
27	The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer Disease and Associated Disorders, 2006, 20, 210-216.	0.6	743
28	APOE predicts amyloidâ€beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 2010, 67, 122-131.	2.8	727
29	APOE4 leads to bloodâ€“brain barrier dysfunction predicting cognitive decline. Nature, 2020, 581, 71-76.	13.7	705
30	The Alzheimer's Disease Centers' Uniform Data Set (UDS). Alzheimer Disease and Associated Disorders, 2009, 23, 91-101.	0.6	684
31	Functional deactivations: Change with age and dementia of the Alzheimer type. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14504-14509.	3.3	674
32	Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease. Archives of Neurology, 1998, 55, 326.	4.9	630
33	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. New England Journal of Medicine, 1992, 327, 1253-1259.	13.9	627
34	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
35	Sleep Quality and Preclinical Alzheimer Disease. JAMA Neurology, 2013, 70, 587.	4.5	570
36	Tau and AÎ² imaging, CSF measures, and cognition in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 338ra66.	5.8	560

#	Article	IF	Citations
37	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 2009, 30, 1026-1036.	1.5	558
38	The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set. Alzheimer Disease and Associated Disorders, 2007, 21, 249-258.	0.6	557
39	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.4	535
40	Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4441-4446.	3.3	529
41	High-precision plasma Î²-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659.	1.5	514
42	Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression. Journal of Neuroscience, 2012, 32, 8890-8899.	1.7	510
43	Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Archives of Neurology, 2001, 58, 1395.	4.9	509
44	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
45	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurology, The, 2013, 12, 957-965.	4.9	471
46	Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 101-118.	1.1	449
47	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. American Journal of Pathology, 2007, 171, 227-240.	1.9	446
48	Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease. Archives of Neurology, 2009, 66, 1469-75.	4.9	434
49	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.4	432
50	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	13.7	425
51	Amyloid Î² concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's and Dementia, 2017, 13, 841-849.	0.4	423
52	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.4	420
53	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 2010, 6, 239-246.	0.4	402
54	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.5	391

#	Article	IF	Citations
55	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
56	YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease. Biological Psychiatry, 2010, 68, 903-912.	0.7	382
57	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	2.8	381
58	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology, 2010, 67, 1473.	4.9	376
59	Validation of clinical diagnostic criteria for Alzheimer's disease. Annals of Neurology, 1988, 24, 17-22.	2.8	366
60	Validity and reliability of the AD8 informant interview in dementia. Neurology, 2006, 67, 1942-1948.	1.5	357
61	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	15.2	351
62	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	3.8	344
63	Spatial correlation between brain aerobic glycolysis and amyloid-Î² (AÎ²) deposition. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17763-17767.	3.3	338
64	Version 3 of the Alzheimer Disease Centersâ€™ Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Disease and Associated Disorders, 2018, 32, 10-17.	0.6	337
65	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimerâ€™s Disease. Science Translational Medicine, 2014, 6, 226ra30.	5.8	320
66	Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 757-768.	1.5	318
67	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	3.0	316
68	Cerebrospinal fluid tau and ptau ₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine, 2009, 1, 371-380.	3.3	315
69	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	3.3	309
70	Decreased cerebrospinal fluid AÎ²₄₂ correlates with brain atrophy in cognitively normal elderly. Annals of Neurology, 2009, 65, 176-183.	2.8	307
71	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.4	302
72	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 582.	4.5	285

#	Article	IF	Citations
73	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
74	Accelerated Weight Loss May Precede Diagnosis in Alzheimer Disease. Archives of Neurology, 2006, 63, 1312.	4.9	282
75	Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-Î² Peptide Deposition Identified With Pittsburgh Compound B. Archives of Neurology, 2009, 66, 1476-81.	4.9	281
76	Serotonin signaling is associated with lower amyloid-Î² levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14968-14973.	3.3	281
77	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.4	266
78	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Annals of Neurology, 2010, 68, 311-318.	2.8	263
79	Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology, 2006, 67, 467-473.	1.5	261
80	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.4	261
81	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
82	The cortical signature of prodromal AD. Neurology, 2009, 72, 1048-1055.	1.5	254
83	Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. Neurobiology of Aging, 2009, 30, 432-440.	1.5	249
84	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between Î²-Amyloid and Tauopathy. JAMA Neurology, 2016, 73, 1070.	4.5	246
85	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	7.1	242
86	Version 3 of the National Alzheimerâ€™s Coordinating Centerâ€™s Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	0.6	241
87	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 2015, 72, 1029.	4.5	237
88	Exercise Engagement as a Moderator of the Effects of <emph type="ital">APOE</emph> Genotype on Amyloid Deposition. Archives of Neurology, 2012, 69, 636.	4.9	235
89	Fluctuations of CSF amyloid-ss levels: Implications for a diagnostic and therapeutic biomarker. Neurology, 2007, 68, 666-669.	1.5	233
90	Effect of sleep on overnight cerebrospinal fluid amyloid Î² kinetics. Annals of Neurology, 2018, 83, 197-204.	2.8	229

#	Article	IF	Citations
91	Effects of Age and Amyloid Deposition on Aî² Dynamics in the Human Central Nervous System. Archives of Neurology, 2012, 69, 51.	4.9	228
92	Loss of Brain Aerobic Glycolysis in Normal Human Aging. Cell Metabolism, 2017, 26, 353-360.e3.	7.2	228
93	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	4.5	227
94	Longitudinal Driving Performance in Early-Stage Dementia of the Alzheimer Type. Journal of the American Geriatrics Society, 2003, 51, 1342-1347.	1.3	220
95	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.4	213
96	Early changes in CSF sTREM2 in dominantly inherited Alzheimerâ€™s disease occur after amyloid deposition and neuronal injury. Science Translational Medicine, 2016, 8, 369ra178.	5.8	211
97	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012, 79, 897-905.	1.5	208
98	Reduced nonâ€“rapid eye movement sleep is associated with tau pathology in early Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	208
99	The effects of aging and Alzheimer's disease on cerebral cortical anatomy: Specificity and differential relationships with cognition. NeuroImage, 2013, 76, 332-344.	2.1	201
100	Rates of progression in mild cognitive impairment and early Alzheimerâ€™s disease. Neurology, 2002, 59, 1034-1041.	1.5	199
101	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
102	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
103	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Human Molecular Genetics, 2012, 21, 4558-4571.	1.4	196
104	Increased in Vivo Amyloid-Î²42 Production, Exchange, and Loss in Presenilin Mutation Carriers. Science Translational Medicine, 2013, 5, 189ra77.	5.8	196
105	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
106	Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type. Archives of Neurology, 2009, 66, 638-45.	4.9	194
107	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology, 2013, 80, 1784-1791.	1.5	194
108	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.5	193

#	Article	IF	Citations
109	Quantitative Analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE, 2013, 8, e73377.	1.1	192
110	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469.	0.4	192
111	Cerebrospinal Fluid AÎ²42/40 Corresponds Better than AÎ²42 to Amyloid PET in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	1.2	191
112	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology, 2018, 91, e859-e866.	1.5	190
113	Alzheimer Disease and Cognitive Reserve. Archives of Neurology, 2008, 65, 1467.	4.9	189
114	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid Î² in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.9	188
115	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	2.1	188
116	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurology, 2015, 72, 1275.	4.5	183
117	Patient's Rating of Cognitive Ability. Archives of Neurology, 2007, 64, 725.	4.9	182
118	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
119	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.4	181
120	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
121	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
122	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.5	174
123	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	1.5	174
124	Mild senile dementia of the alzheimer type: 2. Longitudinal assessment. Annals of Neurology, 1988, 23, 477-484.	2.8	173
125	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
126	Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of Î²-Amyloid 1-42, Total tau, and P-tau₁₈₁ for Identifying Alzheimer Disease Amyloid Plaque Pathology. Archives of Neurology, 2011, 68, 1137.	4.9	161

#	Article	IF	Citations
127	Spatial Navigation in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 77-90.	1.2	156
128	Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurology, 2016, 73, 561.	4.5	154
129	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	3.7	150
130	Association of TMEM106B Gene Polymorphism With Age at Onset in Granulin Mutation Carriers and Plasma Granulin Protein Levels. Archives of Neurology, 2011, 68, 581-6.	4.9	148
131	Age and amyloid effects on human central nervous system amyloidâ€beta kinetics. Annals of Neurology, 2015, 78, 439-453.	2.8	148
132	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146
133	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
134	An Antidepressant Decreases CSF AÎ² Production in Healthy Individuals and in Transgenic AD Mice. Science Translational Medicine, 2014, 6, 236re4.	5.8	142
135	Revised Criteria for Mild Cognitive Impairment May Compromise the Diagnosis of Alzheimer Disease Dementia. Archives of Neurology, 2012, 69, 700-8.	4.9	141
136	â€œNoncognitiveâ€•symptoms of early Alzheimer disease. Neurology, 2015, 84, 617-622.	1.5	140
137	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	2.4	138
138	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
139	Persistent metabolic youth in the aging female brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3251-3255.	3.3	133
140	Visininâ€like proteinâ€1: Diagnostic and prognostic biomarker in Alzheimer disease. Annals of Neurology, 2011, 70, 274-285.	2.8	132
141	PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 370-379.	1.8	132
142	Amyloidâ€beta plaque growth in cognitively normal adults: Longitudinal [¹¹C]Pittsburgh compound B data. Annals of Neurology, 2011, 70, 857-861.	2.8	131
143	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research and Therapy, 2019, 11, 71.	3.0	131
144	Differences in the A?40/A?42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Annals of Neurology, 2000, 48, 201-210.	2.8	126

#	Article	IF	Citations
145	Novel Presenilin 1 Mutation (S170F) Causing Alzheimer Disease With Lewy Bodies in the Third Decade of Life. Archives of Neurology, 2005, 62, 1821.	4.9	125
146	Tau PET in autosomal dominant Alzheimerâ€™s disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	3.7	122
147	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage, 2017, 161, 171-178.	2.1	116
148	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	3.7	116
149	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer's Research and Therapy, 2013, 5, 48.	3.0	115
150	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	4.5	112
151	SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease. PLoS Genetics, 2010, 6, e1001101.	1.5	111
152	Data-driven models of dominantly-inherited Alzheimerâ€™s disease progression. Brain, 2018, 141, 1529-1544.	3.7	111
153	Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1510.e19-1510.e26.	1.5	110
154	Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation. PLoS Genetics, 2014, 10, e1004758.	1.5	109
155	Polygenic risk score of sporadic lateâ€onset Alzheimer's disease reveals a shared architecture with the familial and earlyâ€onset forms. Alzheimer's and Dementia, 2018, 14, 205-214.	0.4	109
156	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature Neuroscience, 2021, 24, 1302-1312.	7.1	105
157	Comparison of a singleâ€channel <scp>EEG</scp> sleep study to polysomnography. Journal of Sleep Research, 2016, 25, 625-635.	1.7	104
158	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimerâ€™s disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	3.0	101
159	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE Îµ4 genotype. Brain, 2018, 141, 1828-1839.	3.7	99
160	Absence of practice effects in preclinical Alzheimerâ€™s disease.. Neuropsychology, 2015, 29, 940-948.	1.0	98
161	Association and Expression Analyses With Single-Nucleotide Polymorphisms in <emph type="ital">TOMM40</emph> in Alzheimer Disease. Archives of Neurology, 2011, 68, 1013.	4.9	97
162	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97

#	Article	IF	Citations
163	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. American Journal of Geriatric Psychiatry, 2016, 24, 1095-1104.	0.6	95
164	Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimer's and Dementia, 2013, 9, S39-44.	0.4	94
165	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain, 2010, 133, 3290-3300.	3.7	93
166	The Brain Chart of Aging: Machineâ€learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. Alzheimer's and Dementia, 2021, 17, 89-102.	0.4	92
167	Cerebrospinal Fluid AÎ²42, Phosphorylated Tau₁₈₁, and Resting-State Functional Connectivity. JAMA Neurology, 2013, 70, 1242-8.	4.5	89
168	Extreme cerebrospinal fluid amyloid Î² levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of Neurology, 2007, 61, 446-453.	2.8	87
169	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	4.9	87
170	Measuring and estimating diagnostic accuracy when there are three ordinal diagnostic groups. Statistics in Medicine, 2006, 25, 1251-1273.	0.8	84
171	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	1.2	84
172	Barriers and Facilitators of African American Participation in Alzheimer Disease Biomarker Research. Alzheimer Disease and Associated Disorders, 2010, 24, S24-S29.	0.6	83
173	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	3.7	83
174	Brief Screening Tests versus Clinical Staging in Senile Dementia of the Alzheimer Type. Journal of the American Geriatrics Society, 1990, 38, 129-135.	1.3	82
175	Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurology, 2015, 72, 789.	4.5	82
176	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	2.8	82
177	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	1.5	80
178	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	3.7	79
179	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	2.1	79
180	Accuracy of Collateral Source Reports in Very Mild to Mild Dementia of the Alzheimer Type. Journal of the American Geriatrics Society, 2003, 51, 819-823.	1.3	78

#	Article	IF	Citations
181	Driving and Dementia of the Alzheimer Type: Beliefs and Cessation Strategies Among Stakeholders. Gerontologist, The, 2005, 45, 676-685.	2.3	78
182	Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Nonâ€“Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1192.	4.5	77
183	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	1.4	76
184	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurology, 2015, 72, 656.	4.5	74
185	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 67, 95-98.	1.5	73
186	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology, 2019, 92, e1567-e1579.	1.5	73
187	Phosphorylated Tau-AÎ²42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimerâ€™s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. Biological Psychiatry, 2014, 75, 723-731.	0.7	72
188	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
189	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	4.9	72
190	Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies. Current Neurology and Neuroscience Reports, 2014, 14, 499.	2.0	70
191	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	3.7	70
192	Preclinical Alzheimer disease and risk of falls. Neurology, 2013, 81, 437-443.	1.5	69
193	Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial. Journal of the American Geriatrics Society, 2000, 48, 558-559.	1.3	68
194	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp>lzheimer <scp>D</scp>isease <scp>N</scp>euroimaging <scp>I</scp>nitiative (<scp>ADNI</scp>) and the <scp>D</scp>ominantly <scp>I</scp>nherited <scp>A</scp>lzheimer <scp>N</scp>etwork (<scp>DIAN</scp>). Neuropathology, 2015, 35, 390-400.	0.7	68
195	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology, 2018, 91, e313-e318.	1.5	68
196	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.5	67
197	Early behavioural changes in familial Alzheimerâ€™s disease in the Dominantly Inherited Alzheimer Network. Brain, 2015, 138, 1036-1045.	3.7	67
198	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	3.7	66

#	Article	IF	Citations
199	Spatially distinct atrophy is linked to Î²-amyloid and tau in preclinical Alzheimer disease. Neurology, 2015, 84, 1254-1260.	1.5	65
200	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
201	Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN).. Neuropsychology, 2014, 28, 19-29.	1.0	63
202	Effect of Race on Prediction of Brain Amyloidosis by Plasma AÎ²42/AÎ²40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.5	63
203	Genetic variants associated with Alzheimerâ€™s disease confer different cerebral cortex cell-type population structure. Genome Medicine, 2018, 10, 43.	3.6	62
204	Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimerâ€™s disease. Brain, 2021, 144, 2852-2862.	3.7	62
205	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	4.1	61
206	Addressing Health Disparities Among Minority Populations. JAMA Neurology, 2020, 77, 1063.	4.5	60
207	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	4.5	59
208	Clinician Assessment of the Driving Competence of Patients with Dementia. Journal of the American Geriatrics Society, 2005, 53, 829-833.	1.3	58
209	Evaluation of Cognitive Impairment in Older Adults. Archives of Neurology, 2007, 64, 718.	4.9	58
210	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
211	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Molecular Neurodegeneration, 2019, 14, 18.	4.4	58
212	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiology of Aging, 2017, 56, 25-32.	1.5	57
213	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. Ageing Research Reviews, 2020, 57, 100994.	5.0	57
214	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
215	Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study. Archives of Neurology, 2011, 68, 1313.	4.9	55
216	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-Îµ4 Carriers. PLoS Genetics, 2013, 9, e1003685.	1.5	55

#	Article	IF	Citations
217	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 87-93.	0.6	52
218	In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. NeuroImage, 2017, 148, 296-304.	2.1	52
219	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. Journal of Alzheimer's Disease, 2020, 74, 1045-1055.	1.2	52
220	Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. Neurology, 2014, 83, 1613-1619.	1.5	51
221	Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. JAMA Neurology, 2015, 72, 1484.	4.5	51
222	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
223	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	1.1	51
224	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	3.9	51
225	Upward drift in cerebrospinal fluid amyloid Î² 42 assay values for more than 10Âyears. Alzheimer's and Dementia, 2018, 14, 62-70.	0.4	50
226	An Interdisciplinary Outreach Model of African American Recruitment for Alzheimer's Disease Research. Gerontologist, The, 2011, 51, S134-S141.	2.3	49
227	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiology of Aging, 2016, 43, 23-33.	1.5	49
228	Crossâ€sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid Î² positron emission tomography pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 245-252.	1.2	49
229	Associations Between Î²-Amyloid Kinetics and the Î²-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurology, 2017, 74, 207.	4.5	47
230	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.4	47
231	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry, 2022, 79, 464.	6.0	47
232	Toward a multifactorial model of Alzheimer disease. Neurobiology of Aging, 2012, 33, 2262-2271.	1.5	45
233	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	1.1	45
234	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.4	45

#	Article	IF	Citations
235	Assessment of the Genetic Architecture of Alzheimerâ€™s Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756.	1.2	45
236	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 1149-1159.	0.4	45
237	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. Neurobiology of Aging, 2016, 37, 208.e1-208.e9.	1.5	44
238	Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 74-82.	1.8	44
239	The relevance of cerebrospinal fluid Î±-synuclein levels to sporadic and familial Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 130.	2.4	44
240	Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System. PLoS ONE, 2014, 9, e89998.	1.1	44
241	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. NeuroImage: Clinical, 2015, 8, 246-252.	1.4	43
242	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, 821-830.	0.4	43
243	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	4.4	43
244	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	5.8	43
245	Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults.. Neuropsychology, 2013, 27, 516-528.	1.0	42
246	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimer's and Dementia, 2016, 12, 614-622.	0.4	42
247	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	1.6	42
248	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.4	42
249	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	1.5	42
250	Socioeconomic Status Mediates Racial Differences Seen Using the <scp>AT(N)</scp> Framework. Annals of Neurology, 2021, 89, 254-265.	2.8	42
251	GPS driving: a digital biomarker for preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 115.	3.0	42
252	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	1.4	41

#	Article	IF	Citations
253	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS Genetics, 2017, 13, e1007045.	1.5	40
254	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology, 2016, 86, 1499-1506.	1.5	39
255	Stability of the Clinical Dementia Rating, 1979-2007. Archives of Neurology, 2009, 66, 773-7.	4.9	38
256	Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. Alzheimer Disease and Associated Disorders, 2019, 33, 87-94.	0.6	38
257	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. Neurology, 2021, 96, e2546-e2557.	1.5	38
258	A deep learning framework identifies dimensional representations of Alzheimerâ€™s Disease from brain structure. Nature Communications, 2021, 12, 7065.	5.8	38
259	Antecedent Biomarkers of Alzheimerâ€™s Disease: The Adult Children Study. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 242-244.	1.2	36
260	The Neuropathology of Alzheimer Disease in African American and White Individuals. Archives of Neurology, 2006, 63, 87.	4.9	36
261	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimerâ€™s disease biomarkers. Neurobiology of Aging, 2015, 36, 1771-1779.	1.5	36
262	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	3.7	36
263	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 2019, 75, 42-50.	1.5	36
264	Ascertainment Bias in the Clinical Diagnosis of Alzheimer Disease. Archives of Neurology, 2010, 67, 1364-9.	4.9	35
265	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. Neurology, 2020, 95, e3104-e3116.	1.5	35
266	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.5	35
267	Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Disease and Associated Disorders, 2017, 31, 69-72.	0.6	34
268	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology, 2017, 88, 1273-1281.	1.5	34
269	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
270	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	4.4	33

#	Article	IF	Citations
271	Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiology of Aging, 2011, 32, S1-S3.	1.5	32
272	Relationship Between Late-Life Hypertension, Blood Pressure, and Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2011, 26, 457-462.	0.9	32
273	Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. F1000Research, 2016, 5, 2376.	0.8	32
274	Physical Activity and Cognitive Trajectories in Cognitively Normal Adults. Alzheimer Disease and Associated Disorders, 2014, 28, 50-57.	0.6	31
275	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	2.1	31
276	Spatial navigation ability predicts progression of dementia symptomatology. Alzheimer's and Dementia, 2020, 16, 491-500.	0.4	31
277	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimerâ€™s amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	2.4	31
278	Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function. PLoS ONE, 2015, 10, e0122920.	1.1	30
279	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 776-785.	0.7	30
280	Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. Journal of the International Neuropsychological Society, 2015, 21, 573-583.	1.2	29
281	Discovery and validation of autosomal dominant Alzheimerâ€™s disease mutations. Alzheimer's Research and Therapy, 2018, 10, 67.	3.0	29
282	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
283	A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study. Journal of Applied Gerontology, 2019, 38, 277-289.	1.0	29
284	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 3825.	5.8	29
285	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 147-155.	1.2	28
286	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. Alzheimer's and Dementia, 2019, 15, 506-514.	0.4	28
287	Effect of escitalopram dose and treatment duration on CSF AÎ² levels in healthy older adults. Neurology, 2020, 95, e2658-e2665.	1.5	28
288	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27

#	Article	IF	Citations
289	In vivo [¹⁸ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2018, 90, e896-e906.	1.5	27
290	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	1.5	27
291	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27
292	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
293	Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. F1000Research, 2016, 5, 2376.	0.8	27
294	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228.	2.1	27
295	Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease. Biological Psychiatry, 2010, 67, 581-583.	0.7	25
296	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. Scientific Reports, 2016, 6, .	1.6	25
297	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 98.	3.0	25
298	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	2.8	25
299	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. Alzheimer's and Dementia, 2020, 16, 589-597.	0.4	25
300	Absence of Effect of Depression on Cognitive Performance in Early-Stage Alzheimer Disease. Archives of Neurology, 2004, 61, 1265-8.	4.9	24
301	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.. Neuropsychology, 2015, 29, 368-381.	1.0	24
302	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248.	3.7	24
303	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. NeuroImage: Clinical, 2020, 26, 102248.	1.4	24
304	Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease. JAMA Neurology, 2021, 78, 141.	4.5	24
305	Neuroinflammation and Myelin Status in Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Normal Aging Brains: A Small Sample Study. Parkinson's Disease, 2019, 2019, 1-12.	0.6	23
306	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-Î² Burden in Cognitively Normal Individuals in Late-Life. Journal of Alzheimer's Disease, 2019, 69, 817-827.	1.2	23

#	Article	IF	Citations
307	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	2.8	23
308	The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia. Journal of the International Neuropsychological Society, 2020, 26, 596-606.	1.2	23
309	Perspective on the â€œAfrican American participation in Alzheimer disease research: Effective strategiesâ€• workshop, 2018. Alzheimer's and Dementia, 2020, 16, 1734-1744.	0.4	23
310	Staging tau pathology with tau PET in Alzheimerâ€™s disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	2.4	23
311	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	1.8	23
312	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. Alzheimer's Research and Therapy, 2018, 10, 69.	3.0	22
313	Translocator protein in late stage Alzheimerâ€™s disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology, 2019, 6, 1423-1434.	1.7	22
314	Amyloid imaging of dutchâ€type hereditary cerebral amyloid angiopathy carriers. Annals of Neurology, 2019, 86, 616-625.	2.8	22
315	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-Î± in APOE4 carriers. Neurobiology of Aging, 2020, 86, 112-122.	1.5	22
316	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. Cerebral Cortex, 2020, 30, 5686-5701.	1.6	22
317	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 825-837.	0.8	22
318	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. Frontiers in Neuroscience, 2018, 12, 209.	1.4	21
319	Association between personality and tau-PET binding in cognitively normal older adults. Brain Imaging and Behavior, 2020, 14, 2122-2131.	1.1	21
320	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of Disease, 2022, 166, 105662.	2.1	21
321	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 96, 233-245.	1.5	20
322	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
323	Proximity to Parental Symptom Onset and Amyloid-Î² Burden in Sporadic Alzheimer Disease. JAMA Neurology, 2018, 75, 608.	4.5	19
324	Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12103.	1.8	19

#	Article	IF	Citations
325	Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. Brain, Behavior, and Immunity, 2021, 94, 299-307.	2.0	19
326	Factors Influencing Successful Lumbar Puncture in Alzheimer Research. Alzheimer Disease and Associated Disorders, 2017, 31, 287-294.	0.6	18
327	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. Journal of Alzheimer's Disease, 2020, 77, 1469-1482.	1.2	18
328	Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 1085-1095.	1.2	18
329	Obesity and White Matter Neuroinflammation Related Edema in Alzheimerâ€™s Disease Dementia Biomarker Negative Cognitively Normal Individuals. Journal of Alzheimer's Disease, 2021, 79, 1801-1811.	1.2	18
330	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
331	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease. JAMA Neurology, 2016, 73, 1125.	4.5	17
332	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. Annals of Neurology, 2018, 84, 741-753.	2.8	17
333	Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. Archives of Clinical Neuropsychology, 2019, 34, 1138-1155.	0.3	17
334	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. Journal of Neurochemistry, 2020, 152, 235-251.	2.1	17
335	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	1.4	17
336	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87.	1.5	17
337	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.5	16
338	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	16
339	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. Neurobiology of Aging, 2016, 38, 104-111.	1.5	15
340	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	3.9	15
341	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	4.5	15
342	Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults. Alzheimer Disease and Associated Disorders, 2018, 32, 101-106.	0.6	14

#	Article	IF	Citations
343	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	1.2	14
344	Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning. Alzheimer Disease and Associated Disorders, 2020, 34, 212-219.	0.6	14
345	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 1119-1129.	1.2	14
346	Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes. Alzheimer's and Dementia, 2021, 17, 653-664.	0.4	14
347	Item response theory analysis of the Clinical Dementia Rating. Alzheimer's and Dementia, 2021, 17, 534-542.	0.4	14
348	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
349	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. Neurobiology of Aging, 2020, 96, 165-175.	1.5	13
350	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.4	13
351	Identifying Preclinical Alzheimerâ€™s Disease Using Everyday Driving Behavior: Proof of Concept. Journal of Alzheimer's Disease, 2021, 79, 1009-1014.	1.2	13
352	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.4	13
353	Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Disease and Associated Disorders, 2018, 32, 291-297.	0.6	12
354	Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals. Journal of Infectious Diseases, 2019, 220, 68-72.	1.9	12
355	Association of education with Aî² burden in preclinical familial and sporadic Alzheimer disease. Neurology, 2020, 95, e1554-e1564.	1.5	12
356	Communicating 5-Year Risk of Alzheimerâ€™s Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results. Journal of Alzheimer's Disease, 2021, 79, 559-572.	1.2	12
357	Lack of association between acute stroke, post-stroke dementia, race, and Î²-amyloid status. NeuroImage: Clinical, 2021, 29, 102553.	1.4	12
358	Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation. Journal of Alzheimer's Disease, 2021, 80, 133-142.	1.2	12
359	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.4	12
360	Dopamine D1Â+ÂD3 receptor density may correlate with parkinson disease clinical features. Annals of Clinical and Translational Neurology, 2021, 8, 224-237.	1.7	12

#	Article	IF	Citations
361	Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	1.6	12
362	Disentangling Alzheimerâ€™s disease neurodegeneration from typical brain ageing using machine learning. Brain Communications, 2022, 4, .	1.5	12
363	Tailored Calendar Journals to Ascertain Falls Among Older Adults. OTJR Occupation, Participation and Health, 2015, 35, 53-59.	0.4	11
364	Neuropsychiatric Symptoms and Alzheimerâ€™s Disease Biomarkers Predict Driving Decline: Brief Report. Journal of Alzheimer's Disease, 2017, 58, 675-680.	1.2	11
365	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 509-513.	1.2	11
366	Depression and Alzheimerâ€™s Disease Biomarkers Predict Driving Decline. Journal of Alzheimer's Disease, 2018, 66, 1213-1221.	1.2	11
367	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. JAMA Network Open, 2019, 2, e1913491.	2.8	11
368	Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 15-20.	0.6	11
369	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa102.	1.5	11
370	Falls Associate with Neurodegenerative Changes in ATN Framework of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 745-752.	1.2	11
371	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease. Acta Neuropathologica Communications, 2022, 10, 29.	2.4	11
372	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1495.	5.8	11
373	Multi-Modal Home Sleep Monitoring in Older Adults. Journal of Visualized Experiments, 2019, , .	0.2	10
374	Anteâ€•and postmortem tau in autosomal dominant and lateâ€•onset Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 2475-2480.	1.7	10
375	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. Journal of Cognitive Neuroscience, 2021, 33, 279-302.	1.1	10
376	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. International Journal of Molecular Sciences, 2021, 22, 2931.	1.8	10
377	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 669-676.	1.8	9
378	Driving in the elderly in health and disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 563-573.	1.0	9

#	Article	IF	Citations
379	Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument. Alzheimer Disease and Associated Disorders, 2020, 34, 112-117.	0.6	9
380	Relationships between bigâ€five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12038.	1.2	9
381	Deciphering the factors that influence participation in studies requiring serial lumbar punctures. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12003.	1.2	9
382	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	1.5	9
383	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	3.7	9
384	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	1.1	9
385	Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. , 2018, 14, 610-616.		8
386	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	2.4	8
387	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. International Journal of Molecular Sciences, 2020, 21, 6047.	1.8	8
388	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. Psychological Science, 2021, 32, 849-860.	1.8	8
389	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. BMJ Open, 2021, 11, e050820.	0.8	8
390	Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults. SLEEP Advances, 2020, 1, zpaa006.	0.1	8
391	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. Alzheimer's and Dementia, 2022, 18, 2570-2581.	0.4	8
392	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.4	7
393	Cerebrospinal fluid AÎ²42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. Neurobiology of Aging, 2021, 98, 116-123.	1.5	7
394	Network dysfunction in cognitively normal APOE Îµ4 carriers is related to subclinical tau. Alzheimer's and Dementia, 2022, 18, 116-126.	0.4	7
395	Cognitively normal APOE Îµ4 carriers have specific elevation of CSF SNAP-25. Neurobiology of Aging, 2021, 102, 64-72.	1.5	7
396	Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity. Journal of Alzheimer's Disease, 2022, 86, 1831-1848.	1.2	7

#	Article	IF	Citations
397	Dissection of the polygenic architecture of neuronal AÎ² production using a large sample of individual iPSC lines derived from Alzheimerâ€™s disease patients. Nature Aging, 2022, 2, 125-139.	5.3	7
398	Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimerâ€™s disease. Sleep, 2022, 45, .	0.6	7
399	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	2.1	7
400	Using the A/T/N Framework to Examine Driving in Preclinical Alzheimerâ€™s Disease. Geriatrics (Switzerland), 2018, 3, 23.	0.6	6
401	The ideological divide in confidence in science and participation in medical research. Scientific Reports, 2021, 11, 3120.	1.6	6
402	Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3172-3186.	3.3	6
403	Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures. Journal of Nuclear Medicine, 2021, , jnumed.120.254490.	2.8	6
404	Intracranial internal carotid artery calcification is not predictive of future cognitive decline. Alzheimer's Research and Therapy, 2022, 14, 32.	3.0	6
405	Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies. Alzheimer Disease and Associated Disorders, 2018, 32, 179-184.	0.6	5
406	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. Journal of Alzheimer's Disease, 2021, 79, 895-903.	1.2	5
407	Latent structure of cognitive performance in the adult children study. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 621-635.	0.8	4
408	O1â€04â€03: COMPARING SMARTPHONEâ€ADMINISTERED COGNITIVE ASSESSMENTS WITH CONVENTIONAL TESTS AND BIOMARKERS IN SPORADIC AND DOMINANTLY INHERITED ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P224.	0.4	4
409	Adaptation of the Clinical Dementia Rating Scale for adults with Down syndrome. Journal of Neurodevelopmental Disorders, 2019, 11, 39.	1.5	4
410	Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults. Journal of Racial and Ethnic Health Disparities, 2020, 7, 269-280.	1.8	4
411	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	1.2	4
412	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.4	4
413	Naturalistic driving measures of route selection associate with resting state networks in older adults. Scientific Reports, 2022, 12, 6486.	1.6	4
414	P4â€108: RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1480.	0.4	3

#	Article	IF	Citations
415	Assessing the Reliability of Reported Medical History in Older Adults. Journal of Alzheimer's Disease, 2020, 78, 643-652.	1.2	3
416	Lack of evidence supporting a role for DPP6 sequence variants in Alzheimerâ€™s disease in the European American population. Acta Neuropathologica, 2021, 141, 623-624.	3.9	3
417	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 153.	3.0	3
418	Beta-Amyloid Moderates the Relationship Between Cortical Thickness and Attentional Control in Middle- and Older-Aged Adults. Neurobiology of Aging, 2022, 112, 181-190.	1.5	3
419	Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 905-924.	1.2	3
420	ICâ€01â€03: Classifying TAU Pet Positivity With [18F]â€AVâ€1451 in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P2.	0.4	2
421	Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class caseâ€"Application to the early diagnosis of Alzheimer disease. Statistical Methods in Medical Research, 2018, 27, 701-714.	0.7	2
422	Twoâ€period linear mixed effects models to analyze clinical trials with runâ€in data when the primary outcome is continuous: Applications to Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 450-457.	1.8	2
423	ICâ€Pâ€021: LONGITUDINAL CHANGES IN FUNCTIONAL CONNECTIVITY IN CONVERSION TO SYMPTOMATIC AD. Alzheimer's and Dementia, 2019, 15, P29.	0.4	2
424	Validation of AD8-Philippines (AD8-P): A Brief Informant-Based Questionnaire for Dementia Screening in the Philippines. International Journal of Alzheimer's Disease, 2021, 2021, 1-9.	1.1	2
425	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.4	2
426	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.4	2
427	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease. , 2015, 11, P533-P534.		1
428	O2â€03â€02: are White Matter Hyperintensities a Core Feature of Alzheimerâ€™s Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2016, 12, P226.	0.4	1
429	P3â€251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2018, 14, P1170.	0.4	1
430	P1â€288: THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)â€ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) COMPARISON STUDY: CHALLENGES AND OPPORTUNITIES. Alzheimer's and Dementia, 2018, 14, P395.	0.4	1
431	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limitsâ€"Application to diagnosing early stage Alzheimer disease. Statistical Methods in Medical Research, 2022, 31, 882-898.	0.7	1
432	Development of a Comprehensive Battery to Collect Social and Structural Determinants of Health (SSDOH) in Cognitively Normal or Very Mildly Impaired Persons. Alzheimer Disease and Associated Disorders, 2022, Publish Ahead of Print, .	0.6	1

#	Article	IF	Citations
433	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
434	[P3â€“263]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER's DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE. Alzheimer's and Dementia, 2017, 13, P1043.	0.4	0
435	Reply to â€œExcess amyloid beta can be degraded in healthy humansâ€. Annals of Neurology, 2018, 83, 650-651.	2.8	0
436	Replication study of ADâ€associated rare variants. Alzheimer's and Dementia, 2022, , .	0.4	0